Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy

April 27, 2026 – Biotechnology, Other, Pharmaceutical – ASGCT 2026, Asgard Therapeutics, gene-based cancer immunotherapies, immunology, onology

• AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system
• Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median survival
• When used in combination with immune checkpoint blockade (ICB), AT-108 demonstrated strong anti-tumor activity, including significantly extending survival and achieving complete tumor regressions
• Findings show AT-108 induces systemic, dose-dependent efficacy with activity across distinct tumor microenvironments, and highlight key biomarker parameters to explore in a future clinical trial.

27 April 2026 — Lund, Sweden — Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces it will present advanced preclinical data on its lead asset AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May, 2026, in Boston, Massachusetts, US.

Fábio Rosa, Co-founder and VP and Head of Research at Asgard Therapeutics, who will give the oral presentation, said: “These data demonstrate the ability of AT-108 to reprogram tumor cells in situ into antigen-presenting cells with high efficiency, systematically driving activation of tumor-specific immune responses within the tumor microenvironment. This work provides clear preclinical evidence supporting our in vivo cell reprogramming platform and represents another milestone for Asgard as we advance AT-108 toward the clinic.”

Shane Olwill, Chief Development Officer at Asgard Therapeutics, said: “We are delighted to have been selected for an oral presentation at ASGCT, which will highlight the progress we have made advancing AT-108 – our first-in-class, off-the-shelf gene-based immunotherapy designed to trigger powerful, personalized anti-cancer responses. Our pioneering approach to tackling cancer is potentially transformative and we are excited by AT-108’s broad potential across multiple cancer types.”

Asgard had previously demonstrated that intratumoral delivery of AT-018 reprograms tumor cells into cDC1-like antigen-presenting cells and works synergistically with immune checkpoint blockade (ICB) to elicit powerful anti-tumor activity.

This new study, being presented at ASGCT 2026, advances AT-108 across four key dimensions. It demonstrates AT-108’s ability to induce systemic anti-tumor immunity in mouse models leading to abscopal effect and regression on non-treated tumors in the same animals; it establishes AT-108 as the optimized clinical candidate following screening of >25 cassette variants; it defines dosing and treatment parameters required for durable responses; and it identifies pharmacodynamic biomarkers associated with reprogramming and immune activation.

Further highlights of the study include that:

• In combination with ICB, Asgard’s approach induced abscopal effects and long-term tumor-free survival in the B16 mouse syngeneic model. These results were associated with increased T cells and NK cells, and reduced regulatory T cells, in both injected and non-injected tumors.
• When used as a monotherapy, AT-108 doubled median survival in B16 and YUMM1.7 mouse models, and induced regression in ID8 ascites mouse model.
• When used in combination with ICB, AT-108 achieved 50% complete response (CR) in B16, and extended survival in the PANC02 immunosuppressed mouse model.
• Cell transduction peaked 1-2 days post injection and persisted for up to 9-15 days, supporting re-dosing every two days to sustain transduction. A three-dose lead cycle was required to achieve CRs, with maintenance dosing improving durability.
• Regarding biomarkers, tumor and peripheral blood analyses identified pharmacodynamic signatures associated with AT-108 activity, including increased cytotoxic T cells, expansion of follicular helper T cells and enrichment of dendritic cells.

The abstract is available to view via the ASGCT interactive program here.

The positive study results come as Asgard progresses AT-108 toward clinical development with a focus on solid tumors, by advancing IND-enabling studies and CMC development.

Details of the oral presentation are as follows:

• Presentation title: Optimized in situ tumor-to-dendritic cell reprogramming by AT-108 adenoviral vector drives local and systemic antitumor immunity
• Presenter: Fabio Rosa, Asgard Therapeutics
• Presentation session: Cancer vaccines and oncolytic viruses I
• Session date and time: 13 May 2026, 03:30 PM – 05:00 PM EDT
• Location: MCEC Room 162AB (Level 1)
• Presentation Time: 04:30 PM – 04:45 PM EDT

About Asgard Therapeutics
Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Asgard Therapeutics aims to establish a pipeline of off-the-shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. Asgard is backed by Novo Holdings, Boehringer Ingelheim Venture Fund, Industrifonden, RV Invest and Johnson & Johnson Innovation – JJDC, Inc. For more information, please visit: www.asgardthx.com